Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction
Anna Meta Dyrvig Kristensen(Frederiksberg Hospital), Borja Ibáñez(Spanish National Centre for Cardiovascular Research), Morten Wang Fagerland(Oslo University Hospital), Michael Mæng(Aarhus University), José A. Barrabés(Centro de Investigación Biomédica en Red), Takeshi Kimura(Municipal Hirakata City Hospital), Stuart Pocock(London School of Hygiene & Tropical Medicine), Roberto Latini(Mario Negri Institute for Pharmacological Research), Kjell Vikenes(Haukeland University Hospital), Sergio Raposeiras‐Roubín(University Hospital Complex Of Vigo), Tomas Jernberg(Karolinska Institutet), Patric Karlström(Ryhov Hospital Jönköping), Robin Hofmann(Stockholm South General Hospital), Xavier Rosselló(Spanish National Centre for Cardiovascular Research), Michael Hecht Olsen(University of Copenhagen), Bertil Lindahl(Uppsala University), Theis Lange(Aalborg University), Jocelyne Benatar(Auckland City Hospital), Valentı́n Fuster(Mount Sinai Hospital), Troels Yndigegn(Lund University), David Erlinge(Lund University), Neiko Ozasa(Kyoto University Hospital), Massimo Piepoli(University of Milan), Claes Held(Uppsala University), Eva Prescott(Frederiksberg Hospital), John Munkhaugen(University of Oslo), Arnhild Bakken(Oslo University Hospital), Dan Atar(Oslo University Hospital), Therese Lucia Friis Holmager(Frederiksberg Hospital)
Cited by 39
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k